Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte

I. Nukaya, M. Yasumoto, T. Iwasaki, M. Ideno, A. Sette, E. Celis, K. Takesako, I. Kato

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing HLA-A24 and CEA. The cytotoxicity to tumor cells by the CTL lines was antigen-specific since it was inhibited by peptide- pulsed cold target cells as well as by anti-class I major histocompatibility complex (MHC) and anti-CD3 monoclonal antibodies (MAbs). The antigen specificity of the 2 CTL lines was examined using several tumor cell lines of various origins and for their peptide-dose responses. The identification of these novel CEA epitopes for CTL offers the opportunity to design and develop epitope-based immunotherapeutic approaches for treating HLA-A24+ patients with tumors that express CEA.

Original languageEnglish (US)
Pages (from-to)92-97
Number of pages6
JournalInternational Journal of Cancer
Volume80
Issue number1
DOIs
StatePublished - Jan 5 1999

Fingerprint

HLA-A24 Antigen
Carcinoembryonic Antigen
Cytotoxic T-Lymphocytes
Epitopes
Peptides
Neoplasms
Tumor Cell Line
Antigens
Antigen-Presenting Cells
Major Histocompatibility Complex
Immunotherapy
Dendritic Cells
Blood Cells
Alleles
Monoclonal Antibodies
Tissue Donors
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. / Nukaya, I.; Yasumoto, M.; Iwasaki, T.; Ideno, M.; Sette, A.; Celis, E.; Takesako, K.; Kato, I.

In: International Journal of Cancer, Vol. 80, No. 1, 05.01.1999, p. 92-97.

Research output: Contribution to journalArticle

Nukaya, I. ; Yasumoto, M. ; Iwasaki, T. ; Ideno, M. ; Sette, A. ; Celis, E. ; Takesako, K. ; Kato, I. / Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. In: International Journal of Cancer. 1999 ; Vol. 80, No. 1. pp. 92-97.
@article{aafd12f1a1f646139f42ae4596a2d586,
title = "Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte",
abstract = "Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing HLA-A24 and CEA. The cytotoxicity to tumor cells by the CTL lines was antigen-specific since it was inhibited by peptide- pulsed cold target cells as well as by anti-class I major histocompatibility complex (MHC) and anti-CD3 monoclonal antibodies (MAbs). The antigen specificity of the 2 CTL lines was examined using several tumor cell lines of various origins and for their peptide-dose responses. The identification of these novel CEA epitopes for CTL offers the opportunity to design and develop epitope-based immunotherapeutic approaches for treating HLA-A24+ patients with tumors that express CEA.",
author = "I. Nukaya and M. Yasumoto and T. Iwasaki and M. Ideno and A. Sette and E. Celis and K. Takesako and I. Kato",
year = "1999",
month = "1",
day = "5",
doi = "10.1002/(SICI)1097-0215(19990105)80:1<92::AID-IJC18>3.0.CO;2-M",
language = "English (US)",
volume = "80",
pages = "92--97",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte

AU - Nukaya, I.

AU - Yasumoto, M.

AU - Iwasaki, T.

AU - Ideno, M.

AU - Sette, A.

AU - Celis, E.

AU - Takesako, K.

AU - Kato, I.

PY - 1999/1/5

Y1 - 1999/1/5

N2 - Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing HLA-A24 and CEA. The cytotoxicity to tumor cells by the CTL lines was antigen-specific since it was inhibited by peptide- pulsed cold target cells as well as by anti-class I major histocompatibility complex (MHC) and anti-CD3 monoclonal antibodies (MAbs). The antigen specificity of the 2 CTL lines was examined using several tumor cell lines of various origins and for their peptide-dose responses. The identification of these novel CEA epitopes for CTL offers the opportunity to design and develop epitope-based immunotherapeutic approaches for treating HLA-A24+ patients with tumors that express CEA.

AB - Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing HLA-A24 and CEA. The cytotoxicity to tumor cells by the CTL lines was antigen-specific since it was inhibited by peptide- pulsed cold target cells as well as by anti-class I major histocompatibility complex (MHC) and anti-CD3 monoclonal antibodies (MAbs). The antigen specificity of the 2 CTL lines was examined using several tumor cell lines of various origins and for their peptide-dose responses. The identification of these novel CEA epitopes for CTL offers the opportunity to design and develop epitope-based immunotherapeutic approaches for treating HLA-A24+ patients with tumors that express CEA.

UR - http://www.scopus.com/inward/record.url?scp=0033524378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033524378&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19990105)80:1<92::AID-IJC18>3.0.CO;2-M

DO - 10.1002/(SICI)1097-0215(19990105)80:1<92::AID-IJC18>3.0.CO;2-M

M3 - Article

C2 - 9935237

AN - SCOPUS:0033524378

VL - 80

SP - 92

EP - 97

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -